Document is current
Any future updates will be listed below
-
Authors
Gallet, Quentin
Bouteloup, Vincent
Locatelli, Maxime
Habert, Marie-Odile
Chupin, Marie
Delrieu, Julien
Lebouvier, Thibaud
Robert, Gabriel
David, Renaud
Bulteau, Samuel
Balageas, Anna-Chloé
Surget, Alexandre https://orcid.org/0000-0002-0333-4634
Belzung, Catherine https://orcid.org/0000-0001-6095-5974
Arlicot, Nicolas https://orcid.org/0000-0001-7087-2312
Ribeiro, Maria-Joao
Barantin, Laurent
Andersson, Frédéric
Cottier, Jean-Philippe
Gissot, Valérie
El-Hage, Wissam
Camus, Vincent https://orcid.org/0000-0002-6845-221X
Gohier, Bénédicte
Desmidt, Thomas https://orcid.org/0000-0003-0949-8389
,
- License Information
-
More Information
Article History
Received: 2 July 2021
Revised: 15 November 2021
Accepted: 19 November 2021
First Online: 10 December 2021
Competing interests
: TD reports personal fees from Lundbeck, Otsuka and Eisai. GR reports personal fees from Janssen & Janssen and Ostuka. RD reports personal fees from Janssen & Janssen, lundbeck, Lilly, BMS, Servier, Eisai and Biogen. WE reports personal fees from Eisai, Janssen, Lundbeck, Otsuka, UCB, Roche and Chugai. VC reports personal fees from Janssen and Bristol Meyers Squibb. All other authors declare no competing interests. As far as we are aware of, among the pharmaceutical companies mentioned here, only Roche is involved in the production of benzodiazepines (namely diazepam, in its marketed form of Valium in France). Neither Roche nor any of the other pharmaceutical companies mentioned here were consulted regarding the planning or analysis of the study.
